The Single-use Upstream Bioprocessing Market is expected to grow at a 15.7 % CAGR during the forecast period for 2023-2031.
The first step in the bioprocess is upstream bioprocessing, which is used to generate cell lines and cultivate them in order to grow the cells by harvesting. Modern cell growth techniques produce bioreactors with noticeably higher titers, shorter time constraints, and more precision. Upstream manufacturing's main objective is to create the environment necessary for cells to manufacture the desired protein. Biomanufacturing is used to develop therapeutic proteins, antibiotics, hormones, enzymes, amino acids, blood substitutes, and alcohol for medical use. Businesses have been forced to adopt cutting-edge technologies like single-use bioprocessing techniques because they are affordable and hasten the production process. This is because there aren't many potential new medicines in the pipeline, blockbuster molecules' patents are about to expire, and there's an increased demand for biologics. Better cell culture medium, more advanced feeding strategies, more resilient cell lines, and bioreactor control suited for specific needs are the main upstream development pillars that have led to the field's overall advancement. The growing demand for biopharmaceuticals and the significant role that single-use bioprocessing systems play in reducing the investment costs and R&D expenses associated with the biologics manufacturing process are two factors driving the market's expansion.
Market Dynamics:
Drivers-
The demand for biopharmaceuticals is anticipated to rise as the senior population grows across key markets since the aged are more susceptible to chronic illnesses & conditions. Companies increasingly favour single-use bioprocessing systems to meet the rising demand for biopharmaceuticals because they improve process efficiency and cut costs associated with labour-intensive procedures like cleaning, sterilization, and maintenance of steel-based bioreactor systems. Single-use bioprocessing technology is used in a variety of biopharmaceutical applications, including filtration, mixing, purification, upstream expression, storage, and separation. Therefore, the single-use bioprocessing market is expanding. Rising manufacturing techniques' productive capacities, the removal of duplicate processes, direct cost savings from cheap labour and material costs, and reduced energy consumption and water use are all contributing reasons to the market's expansion.
Challenges:
There are currently no clear rules or guidelines governing the contamination of single-use bioprocessing systems by extractables and leachables. Leachables are substances that seep into drug products from packaging, closures, and manufacturing elements, and Leachables can be viewed as a subset of extractable as a result. These extractables and leachables are undesirable goods. Single-use bioprocessing goods frequently experience contamination from the container due to leachables because they are constructed of processed plastic materials. In light of their possible effects on product quality and patient health, considerable concerns regarding extractables and leachables resulting from the components of single-use bioprocessing systems may restrain market expansion.
Regional Trends:
During the forecast period, North America (the United States, Canada, and Mexico) is expected to lead the market for single-use upstream bioprocessing. The market for single-use bioprocessing is being adopted due to the growing need for biopharmaceuticals and its benefits, including quick deployment, low risk of product cross-contamination, high energy efficiency, and low risk of product cross-contamination, high energy efficiency, and low water usage. The single-use upstream bioprocessing market in North America is anticipated to be dominated by the United States. The development of breakthrough single-use bioprocessing technologies in industrialized nations like the U.S. and Canada, the aging population, and the growing preference for bioactive compounds are all significant market growth drivers in this region.
Competitive Landscape
Some of The Key Players in the Single-use Upstream Bioprocessing Market:
- Danaher Corporation (Cytiva)
- Sartorius AG
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Corning Incorporated
- Pall Corporation
- General Electric Company (GE Healthcare)
- Eppendorf AG
- Rentschler Biopharma SE
- Lonza
- Meissner Filtration Products, Inc.
- JM BioConnect
- Boehringer Ingelheim GmbH
- Infors A
- Other Prominent Players
The Single-use Upstream Bioprocessing Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 15.7 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Scale, By End Users |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Danaher Corporation (Cytiva), Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, Corning Incorporated, Pall Corporation, General Electric Company (GE Healthcare), Eppendorf AG, Rentschler Biopharma SE, Lonza, Meissner Filtration Products, Inc., JM BioConnect, Boehringer Ingelheim GmbH, Infors A, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
